FDA May OK Generic Forms of Biotech Drugs

APRIL 01, 2004

The FDA is laying the foundation for generic versions of biotechnology medicines. This action could eventually change the market for some of the most pioneering and costly new treatments for cancer and other diseases, according to an article in the Wall Street Journal (February 18, 2004). IMS Health reported that the market for biotechnology drugs totaled $22.3 billion in the 12 months that ended in November 2003.

Currently, there is no process in place for the FDA to approve generic versions of biotech drugs, which are produced through very complicated methods, compared with regular pharmaceuticals. Because the brand name biotech industry is little more than 25 years old, it has had to battle low-cost generic copies of its drugs, and consumers have not gotten the price breaks that come with such competition.

Now, however, with some of the oldest biotech drugs beginning to lose patent protection, the FDA is starting to set the stage for follow-on drugs. The FDA is in the process of putting together scientific guidelines on how to prove that copies are similar to the original medicines.



SHARE THIS SHARE THIS
0

Conference Coverage from ASHP Summer 2017 

Four years after they first launched the Summer Meetings in Minneapolis, Minn., the ASHP 2017 Summer Meetings and Exhibition was in Minneapolis once again.  

 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.